ZBIO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 20.83%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Johnson & Johnson's return on equity of 33.27%.

Zenas BioPharma, Inc. has a consensus price target of $40.75, signalling upside risk potential of 86.93%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -3.9%. Given that Zenas BioPharma, Inc. has higher upside potential than Johnson & Johnson, analysts believe Zenas BioPharma, Inc. is more attractive than Johnson & Johnson.

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.14% to investors and pays a quarterly dividend of $1.30 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Johnson & Johnson's net income of $5.1B. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 60.90x versus 6.19x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 34.4%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Eli Lilly & Co.'s return on equity of 106.26%.

Zenas BioPharma, Inc. has a consensus price target of $40.75, signalling upside risk potential of 86.93%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,183.22 which suggests that it could grow by 11.82%. Given that Zenas BioPharma, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Zenas BioPharma, Inc. is more attractive than Eli Lilly & Co..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.57% to investors and pays a quarterly dividend of $1.50 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 60.90x versus 14.60x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of -301.29%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Nektar Therapeutics's return on equity of -327.67%.

Zenas BioPharma, Inc. has a consensus price target of $40.75, signalling upside risk potential of 86.93%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 210.86%. Given that Nektar Therapeutics has higher upside potential than Zenas BioPharma, Inc., analysts believe Nektar Therapeutics is more attractive than Zenas BioPharma, Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 60.90x versus 37.96x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals, Inc. has a net margin of -335.73% compared to Zenas BioPharma, Inc.'s net margin of 40.17%. Zenas BioPharma, Inc.'s return on equity of -68.2% beat Rigel Pharmaceuticals, Inc.'s return on equity of 273.99%.

Zenas BioPharma, Inc. has a consensus price target of $40.75, signalling upside risk potential of 86.93%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.60 which suggests that it could grow by 51.1%. Given that Zenas BioPharma, Inc. has higher upside potential than Rigel Pharmaceuticals, Inc., analysts believe Zenas BioPharma, Inc. is more attractive than Rigel Pharmaceuticals, Inc..

Zenas BioPharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.111, suggesting its more volatile than the S&P 500 by 11.137%.

Zenas BioPharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zenas BioPharma, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zenas BioPharma, Inc. quarterly revenues are --, which are smaller than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.5M. Zenas BioPharma, Inc.'s net income of -$51.5M is lower than Rigel Pharmaceuticals, Inc.'s net income of $27.9M. Notably, Zenas BioPharma, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 5.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zenas BioPharma, Inc. is 60.90x versus 2.22x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.